Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer
Sentien Biotechnologies Names Dr. Allen Nissenson as Chief Medical Officer
LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles, Emeritus Chief Medical Officer of DaVita Kidney Care, and a member of the Board of Directors of Angion Biomedica Corp and Rockwell Medical, Inc.